On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...

According to a statement that was released by Novavax on Wednesday, it appears that the Food and Drug Administration (FDA) of the United States of America will shortly give the COVID-19 vaccine its ...

mRNA vaccines offer clear advantages and disadvantages ... candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. Sanofi is developing ...

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level. The ...

With some mRNA approaches also using AI to personalise each vaccine to the patient, there are also questions about how to regulate a product that can differ each time it is delivered. As such ...

Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue ...

“She’s an example of this emerging face of cancer that's really quite challenging and quite alarming,” Deignan said.